Evolution of therapeutic paradigms in Hodgkin lymphoma: from “cure-oriented” to “functional cure”

1

Hodgkin lymphoma (HL) is a highly treatable B-cell malignancy with 5-year survival rates exceeding 90% in early-stage patients.
2

Long-term toxicities from conventional therapies, such as secondary malignancies and cardiovascular disease, impact survivors' quality of life.
3

Emerging therapies like brentuximab vedotin and PD-1 inhibitors are reshaping HL treatment, particularly for relapsed/refractory cases.
4

The concept of 'functional cure' emphasizes achieving durable remission while minimizing long-term treatment-related morbidity.
5

Recent clinical trials support immunotherapy-based regimens as a new standard in frontline treatment for Hodgkin lymphoma.

Frontiers In Oncology

by Chengqian Chen, Wei Guo, Xiaoyu Song, Xin Wan, Zhaoxia Li, Haotian Wang, Ou Bai
May 29, 2026

1